Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma Future Oncol
Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study CANCER-AM CANCER SOC
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression Nat Commun
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia J Hematol Oncol
Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Grupo Español de Trasplante Hematopoyético y Terapia Celular Transplantation
Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3) Eur J Cancer